KR102717772B1 - Health functional food composition for antioxidant activity and immune-enhancing - Google Patents
Health functional food composition for antioxidant activity and immune-enhancing Download PDFInfo
- Publication number
- KR102717772B1 KR102717772B1 KR1020240049858A KR20240049858A KR102717772B1 KR 102717772 B1 KR102717772 B1 KR 102717772B1 KR 1020240049858 A KR1020240049858 A KR 1020240049858A KR 20240049858 A KR20240049858 A KR 20240049858A KR 102717772 B1 KR102717772 B1 KR 102717772B1
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- parts
- vitamin
- functional food
- health functional
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 54
- 235000013376 functional food Nutrition 0.000 title claims abstract description 22
- 230000036541 health Effects 0.000 title claims abstract description 22
- 230000003078 antioxidant effect Effects 0.000 title claims description 26
- 239000000843 powder Substances 0.000 claims abstract description 34
- 238000002360 preparation method Methods 0.000 claims abstract description 21
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims abstract description 20
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 20
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 20
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims abstract description 20
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims abstract description 20
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 18
- 235000021537 Beetroot Nutrition 0.000 claims abstract description 17
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims abstract description 16
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims abstract description 16
- 229930003471 Vitamin B2 Natural products 0.000 claims abstract description 16
- 239000012141 concentrate Substances 0.000 claims abstract description 16
- 229960002477 riboflavin Drugs 0.000 claims abstract description 16
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims abstract description 16
- 235000020240 turmeric extract Nutrition 0.000 claims abstract description 16
- 229940052016 turmeric extract Drugs 0.000 claims abstract description 16
- 239000008513 turmeric extract Substances 0.000 claims abstract description 16
- 235000019164 vitamin B2 Nutrition 0.000 claims abstract description 16
- 239000011716 vitamin B2 Substances 0.000 claims abstract description 16
- 235000002789 Panax ginseng Nutrition 0.000 claims abstract description 15
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims abstract description 15
- 229930003451 Vitamin B1 Natural products 0.000 claims abstract description 14
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims abstract description 14
- 229960003495 thiamine Drugs 0.000 claims abstract description 14
- 235000010374 vitamin B1 Nutrition 0.000 claims abstract description 14
- 239000011691 vitamin B1 Substances 0.000 claims abstract description 14
- 239000011726 vitamin B6 Substances 0.000 claims abstract description 14
- 235000019158 vitamin B6 Nutrition 0.000 claims abstract description 14
- 229940011671 vitamin b6 Drugs 0.000 claims abstract description 14
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 12
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims abstract description 12
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 claims abstract description 12
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 12
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 12
- 229960001471 sodium selenite Drugs 0.000 claims abstract description 12
- 235000015921 sodium selenite Nutrition 0.000 claims abstract description 12
- 239000011781 sodium selenite Substances 0.000 claims abstract description 12
- 235000005282 vitamin D3 Nutrition 0.000 claims abstract description 12
- 239000011647 vitamin D3 Substances 0.000 claims abstract description 12
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims abstract description 12
- 229940021056 vitamin d3 Drugs 0.000 claims abstract description 12
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 claims abstract description 11
- 229960002079 calcium pantothenate Drugs 0.000 claims abstract description 11
- 229940099596 manganese sulfate Drugs 0.000 claims abstract description 11
- 239000011702 manganese sulphate Substances 0.000 claims abstract description 11
- 235000007079 manganese sulphate Nutrition 0.000 claims abstract description 11
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 claims abstract description 11
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 10
- RWSXRVCMGQZWBV-PHDIDXHHSA-N L-Glutathione Natural products OC(=O)[C@H](N)CCC(=O)N[C@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-PHDIDXHHSA-N 0.000 claims abstract description 10
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims abstract description 10
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 10
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 10
- 229960002685 biotin Drugs 0.000 claims abstract description 10
- 235000020958 biotin Nutrition 0.000 claims abstract description 10
- 239000011616 biotin Substances 0.000 claims abstract description 10
- 229940041514 candida albicans extract Drugs 0.000 claims abstract description 10
- 229960000304 folic acid Drugs 0.000 claims abstract description 10
- 235000019152 folic acid Nutrition 0.000 claims abstract description 10
- 239000011724 folic acid Substances 0.000 claims abstract description 10
- 239000008103 glucose Substances 0.000 claims abstract description 10
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims abstract description 10
- 239000000377 silicon dioxide Substances 0.000 claims abstract description 10
- 235000012239 silicon dioxide Nutrition 0.000 claims abstract description 10
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 10
- 239000011718 vitamin C Substances 0.000 claims abstract description 10
- 239000012138 yeast extract Substances 0.000 claims abstract description 10
- 239000011787 zinc oxide Substances 0.000 claims abstract description 10
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims abstract description 9
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims abstract description 9
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims abstract description 9
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract description 9
- 239000003963 antioxidant agent Substances 0.000 claims description 18
- 235000006708 antioxidants Nutrition 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 16
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 claims description 15
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 9
- 239000000284 extract Substances 0.000 claims description 5
- 235000005152 nicotinamide Nutrition 0.000 claims description 4
- 239000011570 nicotinamide Substances 0.000 claims description 4
- 235000013361 beverage Nutrition 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 229960003966 nicotinamide Drugs 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 16
- 230000036039 immunity Effects 0.000 abstract description 14
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 abstract description 6
- 230000003064 anti-oxidating effect Effects 0.000 abstract description 4
- 229960001296 zinc oxide Drugs 0.000 abstract description 4
- 230000001976 improved effect Effects 0.000 abstract description 2
- 230000000052 comparative effect Effects 0.000 description 20
- 238000004519 manufacturing process Methods 0.000 description 17
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 14
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 9
- 210000002540 macrophage Anatomy 0.000 description 9
- 102000004889 Interleukin-6 Human genes 0.000 description 7
- 108090001005 Interleukin-6 Proteins 0.000 description 7
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 7
- 229940100601 interleukin-6 Drugs 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 230000036737 immune function Effects 0.000 description 6
- 230000015788 innate immune response Effects 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 150000001720 carbohydrates Chemical class 0.000 description 5
- 235000014633 carbohydrates Nutrition 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000003642 reactive oxygen metabolite Substances 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 235000019197 fats Nutrition 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 229920006008 lipopolysaccharide Polymers 0.000 description 4
- 230000022558 protein metabolic process Effects 0.000 description 4
- 230000002292 Radical scavenging effect Effects 0.000 description 3
- 230000004721 adaptive immunity Effects 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 206010016256 fatigue Diseases 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 230000036542 oxidative stress Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000033289 adaptive immune response Effects 0.000 description 2
- -1 and for example Chemical compound 0.000 description 2
- 230000006851 antioxidant defense Effects 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 229910052804 chromium Inorganic materials 0.000 description 2
- 239000011651 chromium Substances 0.000 description 2
- 239000013065 commercial product Substances 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000005965 immune activity Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 210000005007 innate immune system Anatomy 0.000 description 2
- 230000017306 interleukin-6 production Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 230000006433 tumor necrosis factor production Effects 0.000 description 2
- OAVRWNUUOUXDFH-UHFFFAOYSA-H 2-hydroxypropane-1,2,3-tricarboxylate;manganese(2+) Chemical compound [Mn+2].[Mn+2].[Mn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O OAVRWNUUOUXDFH-UHFFFAOYSA-H 0.000 description 1
- DHHFDKNIEVKVKS-FMOSSLLZSA-N Betanin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC(C[C@H]2C([O-])=O)=C1[N+]2=C\C=C\1C=C(C(O)=O)N[C@H](C(O)=O)C/1 DHHFDKNIEVKVKS-FMOSSLLZSA-N 0.000 description 1
- DHHFDKNIEVKVKS-MVUYWVKGSA-N Betanin Natural products O=C(O)[C@@H]1NC(C(=O)O)=C/C(=C\C=[N+]/2\[C@@H](C(=O)[O-])Cc3c\2cc(O)c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c3)/C1 DHHFDKNIEVKVKS-MVUYWVKGSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 239000011627 DL-alpha-tocopherol Substances 0.000 description 1
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 1
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003537 Vitamin B3 Natural products 0.000 description 1
- 229930003571 Vitamin B5 Natural products 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 235000012677 beetroot red Nutrition 0.000 description 1
- 239000001654 beetroot red Substances 0.000 description 1
- 235000002185 betanin Nutrition 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000007177 brain activity Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 208000037824 growth disorder Diseases 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000011565 manganese chloride Substances 0.000 description 1
- 235000002867 manganese chloride Nutrition 0.000 description 1
- 229940099607 manganese chloride Drugs 0.000 description 1
- 239000011564 manganese citrate Substances 0.000 description 1
- 235000014872 manganese citrate Nutrition 0.000 description 1
- 229940097206 manganese citrate Drugs 0.000 description 1
- 239000011683 manganese gluconate Substances 0.000 description 1
- 235000014012 manganese gluconate Nutrition 0.000 description 1
- 229940072543 manganese gluconate Drugs 0.000 description 1
- OXHQNTSSPHKCPB-IYEMJOQQSA-L manganese(2+);(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Mn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OXHQNTSSPHKCPB-IYEMJOQQSA-L 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229940057917 medium chain triglycerides Drugs 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000037257 muscle growth Effects 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 231100000065 noncytotoxic Toxicity 0.000 description 1
- 230000002020 noncytotoxic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000003504 photosensitizing agent Substances 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229940091258 selenium supplement Drugs 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 230000007103 stamina Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000012646 vaccine adjuvant Substances 0.000 description 1
- 229940124931 vaccine adjuvant Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019160 vitamin B3 Nutrition 0.000 description 1
- 239000011708 vitamin B3 Substances 0.000 description 1
- 235000009492 vitamin B5 Nutrition 0.000 description 1
- 239000011675 vitamin B5 Substances 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/302—Foods, ingredients or supplements having a functional effect on health having a modulating effect on age
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
- A23V2250/2104—Anthocyanins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
- A23V2250/2112—Curcumin, turmeric
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
- A23V2250/2124—Ginseng
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/70—Vitamins
- A23V2250/704—Vitamin B
- A23V2250/7044—Vitamin B2
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
본 발명은 항산화 및 면역증강용 건강기능식품 조성물에 관한 것으로, 보다 상세하게는 레드비트농축분말, 강황추출물, 홍삼분말, 비타민B2, 비타민B1, 니코틴산아미드, 판토텐산칼슘, 비타민B6, 비오틴, 엽산, 아셀렌산나트륨혼합제제, 비타민C, 비타민D3혼합제제, 건조효모, 산화아연, 황산망간, 히알루론산혼합제제, L-글루타치온 효모추출물, 스테아린산마그네슘, 이산화규소, 하이드록시프로필 셀룰로오스 및 정제포도당을 포함하고, 항산화 및 면역력 개선 효과가 향상된 레드비트농축분말, 강황추출물, 홍삼분말 및 비타민B2의 혼합조성을 갖는 건강기능식품 조성물에 관한 것이다.The present invention relates to a health functional food composition for antioxidation and immunity enhancement, and more specifically, to a health functional food composition having a mixed composition of red beet concentrate powder, turmeric extract, red ginseng powder, vitamin B2, vitamin B1, nicotinamide, calcium pantothenate, vitamin B6, biotin, folic acid, sodium selenite mixed preparation, vitamin C, vitamin D3 mixed preparation, dried yeast, zinc oxide, manganese sulfate, hyaluronic acid mixed preparation, L-glutathione yeast extract, magnesium stearate, silicon dioxide, hydroxypropyl cellulose and refined glucose, and having an improved antioxidation and immunity enhancement effect, the composition comprising:
Description
본 발명은 항산화 및 면역증강용 건강기능식품 조성물에 관한 것으로, 보다 상세하게는 항산화 및 면역력 개선 효과가 향상된 혼합조성을 갖는 기능성 조성물 및 이를 포함하는 항산화 및 면역력 증강용 건강기능식품 조성물에 관한 것이다.The present invention relates to a health functional food composition for antioxidant and immune enhancement, and more specifically, to a functional composition having a mixed composition with enhanced antioxidant and immune enhancement effects, and a health functional food composition for antioxidant and immune enhancement containing the same.
인체에서 산소를 소비하는 과정으로 인해 불가피하게 발생하는 부산물인 과산화수소(hydrogen peroxide, H2O2), 초과산화음이온(superoxide anion, O2 -), 하이드록실라디칼(hydroxyl radical, OH) 등과 같은 활성 산소종(reactive oxygen species; ROS)은 생체 내에서의 높은 반응성으로 인하여 독성을 유발한다. 이들 활성 산소는 여러 가지 환경적 요인이나 병리적인 요인들에 의하여 과잉으로 생성될 수 있으며 이들의 과다 생성과 활성 산소를 제거하고 방어하는 항산화 방어체계의 결핍은 항산화 방어체계의 불균형을 일으켜, 산화적 스트레스를 발생시킨다. Reactive oxygen species (ROS), such as hydrogen peroxide (H 2 O 2 ), superoxide anion (O 2 - ), and hydroxyl radical (OH), which are inevitably generated as by-products of the process of consuming oxygen in the human body, cause toxicity due to their high reactivity in the body. These reactive oxygen species can be excessively produced due to various environmental or pathological factors, and their excessive production and deficiency of the antioxidant defense system that removes and defends against reactive oxygen species cause an imbalance in the antioxidant defense system, resulting in oxidative stress.
면역은 체내에 존재하는 자기방어체계로서 인체가 외부로부터 침입해오는 각종 물질이나 생명체를 자기 자신에 대한 이물질로 인식하여 제거하고 대사시키는 과정이다, 외부 자극에 의한 손상이나 병원 미생물의 침입으로부터 자신을 방어하기도 하지만, 염증반응 등과 같이 자기 자신의 조직에 손상을 줄 수도 있다. 면역기능의 변화를 조절하여 정상으로 회복시키거나 변화의 폭을 줄여 주는 작용으로 면역기능 억제나 면역기능 증강으로 구분된다.Immunity is a self-defense system that exists in the body. It is a process in which the body recognizes various substances or organisms that invade from the outside as foreign substances and eliminates and metabolizes them. It defends itself from damage caused by external stimuli or invasion by pathogenic microorganisms, but it can also damage its own tissues, such as in inflammatory reactions. It is divided into immune function suppression and immune function enhancement by controlling changes in immune function to restore it to normal or reduce the extent of change.
사이토카인(Cytokines)은 선천 면역과 적응 면역에 관여하는 세포에서 분비되는 단백질로서 적응면역반응의 활성화 단계에서 림프구의 성장과 분화를 자극하고, 선천면역과 적응면역의 작동 단계에서 여러 종류의 작동세포들을 활성화시켜 미생물과 항원들을 제거한다. 그 중 TNF(Tomor necrosis factor)는 선천 면역을 매개하고 조절하는 사이토카인으로, 활성화된 대식세포에서 주로 생산된다. IL-6(Interleukin-6)는 선천 면역과 적응면역 모두에서 기능을 하는 사이토카인이다. 선천면역에서 골수 전구세포로부터 호중구의 생산을 유도하며, 적응면역에서는 항체 생산자로 분화된 B 림프구의 성장을 자극한다. 또한 항염증성 사이토카인의 생산을 자극함과 조절 T 림프구의 생성과 작용을 억제하여 세포매개 면역반응을 촉진한다. 대식세포와 내피세포, T 림프구에서 생성된다. Cytokines are proteins secreted by cells involved in innate and adaptive immunity. They stimulate the growth and differentiation of lymphocytes during the activation phase of the adaptive immune response, and activate various types of effector cells during the operation phase of the innate and adaptive immune responses to eliminate microorganisms and antigens. Among them, TNF (tumor necrosis factor) is a cytokine that mediates and regulates innate immunity, and is mainly produced by activated macrophages. IL-6 (interleukin-6) is a cytokine that functions in both innate and adaptive immunity. In innate immunity, it induces the production of neutrophils from bone marrow progenitor cells, and in adaptive immunity, it stimulates the growth of B lymphocytes differentiated into antibody producers. It also stimulates the production of anti-inflammatory cytokines and inhibits the production and function of regulatory T lymphocytes, thereby promoting cell-mediated immune responses. It is produced by macrophages, endothelial cells, and T lymphocytes.
바쁜 현대사회에 접어들면서 나이에 관계없이 아동부터 수험생, 노인들이 만성피로에 시달리거나 면역력이 저하되어 건강관리에 문제를 겪는 경우가 많아지고 있다. 스트레스, 과로, 수면부족, 과음, 불균형한 식사, 각종 환경공해 노출 등은 면역력 저하의 주된 원인으로 알려져 있다. 이러한 문제들로 본래 우리 몸이 가지고 있는 자연치유기능이 점차 약화되어 아토피성 피부염, 알레르기 비염, 두드러기, 과민성폐렴, 중이염, 허약체질, 식욕부진, 성장장애, 집중력 저하, 잦은 감기, 호흡기 바이러스 등과 같은 다양한 질환 또는 증상이 유발된다.As we enter a busy modern society, many people, regardless of age, from children to test takers and the elderly, are suffering from chronic fatigue or having health problems due to weakened immunity. Stress, overwork, lack of sleep, excessive drinking, unbalanced diet, exposure to various environmental pollutants, etc. are known to be the main causes of weakened immunity. These problems gradually weaken the body's natural healing function, causing various diseases or symptoms such as atopic dermatitis, allergic rhinitis, urticaria, hypersensitivity pneumonia, otitis media, weak constitution, loss of appetite, growth disorder, decreased concentration, frequent colds, respiratory viruses, etc.
현재까지 면역력 증진을 목적으로 한 수많은 백신 면역증강제가 개발 중이지만 실제로 사용허가를 받은 면역증강제는 5~6종에 지나지 않는다. 가장 널리 사용되고 있는 면역증강제인 명반항원보강제(alum adjuvant)는 상대적으로 낮은 면역증강 효율과 자가면역반응 발생과 같은 부작용 보고가 있다. 면역증강제의 안전성 문제로 인해, 상대적으로 안전한 건강기능식품의 사용이 보다 바람직한 방안으로 지목되어, 이에 대한 연구가 활발히 진행되고 있다.Currently, many vaccine adjuvants are being developed for the purpose of enhancing immunity, but only 5~6 adjuvants have actually been approved for use. The most widely used adjuvant, alum adjuvant, has relatively low immune enhancement efficacy and has been reported to have side effects such as autoimmune reactions. Due to safety issues with adjuvants, the use of relatively safe health functional foods is considered a more desirable option, and research on this is actively being conducted.
이에 본 발명자들은 면역증강제로서 안전한 건강기능식품을 개발하기 위해 노력한 결과, 레드비트농축분말, 강황추출물, 홍삼분말, 비타민B2, 비타민B1, 니코틴산아미드, 판토텐산칼슘, 비타민B6, 비오틴, 엽산, 아셀렌산나트륨혼합제제, 비타민C, 비타민D3혼합제제, 건조효모, 산화아연, 황산망간, 히알루론산혼합제제, L-글루타치온 효모추출물, 스테아린산마그네슘, 이산화규소, 하이드록시프로필 셀룰로오스 및 정제포도당을 포함하는 건강기능식품 조성물을 제조하고, 상기 조성물의 항산화 및 면역력 개선 효과를 보다 향상시킬 수 있는 레드비트농축분말, 강황추출물, 홍삼분말 및 비타민B2의 혼합조성을 확인하였다. 따라서, 본 발명자들은 상기 건강기능식품 조성물이 항산화 및 면역증강용 건강기능식품 조성물로 유용하게 이용될 수 있음을 밝힘으로써, 본 출원에 이르게 되었다. Accordingly, the inventors of the present invention have made efforts to develop a safe health functional food as an immune-enhancing agent, and as a result, they have manufactured a health functional food composition including red beet concentrate powder, turmeric extract, red ginseng powder, vitamin B2, vitamin B1, nicotinamide, calcium pantothenate, vitamin B6, biotin, folic acid, sodium selenite mixed preparation, vitamin C, vitamin D3 mixed preparation, dried yeast, zinc oxide, manganese sulfate, hyaluronic acid mixed preparation, L-glutathione yeast extract, magnesium stearate, silicon dioxide, hydroxypropyl cellulose, and refined glucose, and have confirmed a mixed composition of red beet concentrate powder, turmeric extract, red ginseng powder, and vitamin B2 that can further enhance the antioxidant and immune-enhancing effects of the composition. Accordingly, the inventors of the present invention have revealed that the health functional food composition can be usefully used as a health functional food composition for antioxidant and immune-enhancing effects, and have thus led to the present application.
본 발명의 목적은 항산화 및 면역력 개선 효과를 나타내는 기능성 조성물 및 이를 포함하는 건강기능식품 조성물을 제공하는 것이다.The purpose of the present invention is to provide a functional composition exhibiting antioxidant and immune system-improving effects and a health functional food composition containing the same.
본 발명의 목적을 달성하기 위하여, 본 발명은 레드비트농축분말, 강황추출물, 홍삼분말, 비타민B2, 비타민B1 또는 이의 염, 니코틴산아미드, 판토텐산칼슘, 비타민B6 또는 이의 염, 비오틴, 엽산, 아셀렌산나트륨혼합제제, 비타민C, 비타민D3혼합제제, 건조효모, 산화아연, 황산망간, 히알루론산혼합제제, L-글루타치온 효모추출물, 스테아린산마그네슘, 이산화규소, 하이드록시프로필 셀룰로오스 및 정제포도당을 포함하는 항산화 및 면역증강용 건강기능식품 조성물을 제공한다.In order to achieve the object of the present invention, the present invention provides an antioxidant and immune-enhancing health functional food composition comprising red beet concentrate powder, turmeric extract, red ginseng powder, vitamin B2, vitamin B1 or a salt thereof, nicotinamide, calcium pantothenate, vitamin B6 or a salt thereof, biotin, folic acid, sodium selenite mixed preparation, vitamin C, vitamin D3 mixed preparation, dried yeast, zinc oxide, manganese sulfate, hyaluronic acid mixed preparation, L-glutathione yeast extract, magnesium stearate, silicon dioxide, hydroxypropyl cellulose and refined glucose.
본 발명에 따른 건강기능식품 조성물은 레드비트농축분말, 강황추출물, 홍삼분말, 비타민B2, 비타민B1, 니코틴산아미드, 판토텐산칼슘, 비타민B6, 비오틴, 엽산, 아셀렌산나트륨혼합제제, 비타민C, 비타민D3혼합제제, 건조효모, 산화아연, 황산망간, 히알루론산혼합제제, L-글루타치온 효모추출물, 스테아린산마그네슘, 이산화규소, 하이드록시프로필 셀룰로오스 및 정제포도당을 포함하고, 항산화 및 면역력 개선 효과가 향상된 레드비트농축분말, 강황추출물, 홍삼분말 및 비타민B2의 혼합조성을 갖는 바, 항산화 및 면역증강용 건강기능식품으로 유용하게 이용될 수 있다.The health functional food composition according to the present invention comprises red beet concentrate powder, turmeric extract, red ginseng powder, vitamin B2, vitamin B1, nicotinamide, calcium pantothenate, vitamin B6, biotin, folic acid, sodium selenite mixed preparation, vitamin C, vitamin D3 mixed preparation, dried yeast, zinc oxide, manganese sulfate, hyaluronic acid mixed preparation, L-glutathione yeast extract, magnesium stearate, silicon dioxide, hydroxypropyl cellulose and refined glucose, and has a mixed composition of red beet concentrate powder, turmeric extract, red ginseng powder and vitamin B2 with enhanced antioxidant and immune-enhancing effects, and can be usefully used as a health functional food for antioxidant and immune-enhancing effects.
도 1은 RAW 264.7 세포에서 본 발명의 일 실시예에 따라 제조된 조성물 처리에 따른 세포 생존율을 확인한 도이다.
도 2는 본 발명의 일 실시예에 따라 제조된 조성물로 처리된 RAW 264.7 세포의 세포 배양액 내 존재하는 NO 농도를 확인한 도이다.
도 3은 본 발명의 일 실시예에 따라 제조된 조성물로 처리된 RAW 264.7 세포의 세포 배양액 내 존재하는 TNF-α 농도를 확인한 도이다.
도 4는 본 발명의 일 실시예에 따라 제조된 조성물로 처리된 RAW 264.7 세포의 세포 배양액 내 존재하는 IL-6 농도를 확인한 도이다.Figure 1 is a diagram confirming cell viability according to treatment with a composition manufactured according to one embodiment of the present invention in RAW 264.7 cells.
FIG. 2 is a diagram confirming the NO concentration present in a cell culture of RAW 264.7 cells treated with a composition manufactured according to one embodiment of the present invention.
FIG. 3 is a diagram confirming the concentration of TNF-α present in a cell culture of RAW 264.7 cells treated with a composition manufactured according to one embodiment of the present invention.
FIG. 4 is a diagram confirming the concentration of IL-6 present in a cell culture of RAW 264.7 cells treated with a composition manufactured according to one embodiment of the present invention.
이하, 본 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail.
본 발명은 레드비트농축분말, 강황추출물, 홍삼분말, 비타민B2, 비타민B1 또는 이의 염, 니코틴산아미드, 판토텐산칼슘, 비타민B6 또는 이의 염, 비오틴, 엽산, 아셀렌산나트륨혼합제제, 비타민C, 비타민D3혼합제제, 건조효모, 산화아연, 황산망간, 히알루론산혼합제제, L-글루타치온 효모추출물, 스테아린산마그네슘, 이산화규소, 하이드록시프로필 셀룰로오스 및 정제포도당을 포함하는 항산화 및 면역증강용 건강기능식품 조성물을 제공한다.The present invention provides an antioxidant and immune-enhancing health functional food composition comprising red beet concentrate powder, turmeric extract, red ginseng powder, vitamin B2, vitamin B1 or a salt thereof, nicotinamide, calcium pantothenate, vitamin B6 or a salt thereof, biotin, folic acid, a sodium selenite mixed preparation, vitamin C, a vitamin D3 mixed preparation, dried yeast, zinc oxide, manganese sulfate, a hyaluronic acid mixed preparation, L-glutathione yeast extract, magnesium stearate, silicon dioxide, hydroxypropyl cellulose, and refined glucose.
본 발명에서, 상기 레드비트농축분말은 안토시아닌(anthocyanin) 및 베타닌(betanin)을 활성 성분으로 포함하고, 각종 비타민과 미네랄 등이 풍부하게 함유되어 있어 항산화 및 면역력을 높여주는데 도움이 된다. 상기 레드비트농축분말은 시판되는 것 또는 제조되는 것 등을 제한 없이 사용할 수 있다. 레드비트농축분말이 제조된 것이라면 그 구체적인 제조방법을 제한하지 않으나, 예시적으로 세척한 레드비트를 저온압착추출방식, 예컨대 45 내지 50℃에서 24 내지 48시간 동안 추출하고 농축한 후 분말화한 것일 수 있다. 또한, 상기 레드비트농축분말은 8 내지 12 중량부로 포함될 수 있고, 구체적으로 9 내지 11 중량부로 포함될 수 있다.In the present invention, the red beet concentrate powder contains anthocyanin and betanin as active ingredients, and is rich in various vitamins and minerals, thereby helping to enhance antioxidation and immunity. The red beet concentrate powder may be used without limitation in either commercially available or manufactured products. If the red beet concentrate powder is manufactured, the specific manufacturing method is not limited, but as an example, washed red beets may be extracted and concentrated using a low-temperature pressing method, for example, at 45 to 50°C for 24 to 48 hours, and then powdered. In addition, the red beet concentrate powder may be included in an amount of 8 to 12 parts by weight, and specifically, may be included in an amount of 9 to 11 parts by weight.
본 발명에서, 상기 강황추출물은 폴리페놀 성분인 커큐민을 포함하여 항산화 및 면역력을 높여주는데 도움이 된다. 상기 강황추출물은 시판되는 것 또는 제조되는 것 등을 제한 없이 사용할 수 있다. 강황추출물이 제조된 것이라면 그 구체적인 제조방법을 제한하지 않으나, 예시적으로 상기 추출물은 물, 탄소수 1 내지 6의 저급 알코올 또는 이들의 혼합물로 추출될 수 있고, 보다 구체적으로 물로 추출될 수 있다. 또한, 10℃ 내지 100℃에서 1 내지 72 시간 동안 추출 후 여과하고, 여과된 추출물을 진공 회전 농축기로 감압 농축하여 분말화한 것일 수 있다. 또한, 상기 강황추출물은 8 내지 12 중량부로 포함될 수 있고, 구체적으로 9 내지 11 중량부로 포함될 수 있다.In the present invention, the turmeric extract contains curcumin, a polyphenol component, which helps to enhance antioxidation and immunity. The turmeric extract may be used without limitation in a commercially available or manufactured one. If the turmeric extract is manufactured, the specific manufacturing method thereof is not limited, but for example, the extract may be extracted with water, a lower alcohol having 1 to 6 carbon atoms, or a mixture thereof, and more specifically, may be extracted with water. In addition, the extract may be extracted at 10° C. to 100° C. for 1 to 72 hours, filtered, and the filtered extract may be concentrated under reduced pressure using a vacuum rotary concentrator to be powdered. In addition, the turmeric extract may be included in an amount of 8 to 12 parts by weight, and specifically, may be included in an amount of 9 to 11 parts by weight.
본 발명에서, 상기 홍삼 분말은 홍삼다당체를 포함하여 대식세포의 활성 유도를 통한 선천적 면역을 촉진할 수 있다. 또한, 상기 홍삼 분말은 0.005 내지 0.025 중량부로 포함될 수 있고, 0.01 내지 0.02 중량부로 포함될 수 있다. In the present invention, the red ginseng powder can promote innate immunity by inducing the activation of macrophages by including red ginseng polysaccharide. In addition, the red ginseng powder can be included in an amount of 0.005 to 0.025 parts by weight, and can be included in an amount of 0.01 to 0.02 parts by weight.
본 발명에서, 상기 비타민B2는 체내 에너지 생성에 필요하고, 광감작제 역할을 하여 광역학 pathogenic reduction 즉 세균, 바이러스 박멸, 소멸 효과가 있다. 또한, 상기 비타민B2는 시중에 나와있는 것 중 식약처 허용범위 내에서 함량이 가장 높은 것이 특징이다. 구체적으로 상기 비타민B2는 38 내지 42 중량부로 포함될 수 있고, 보다 구체적으로 39 내지 41 중량부로 포함될 수 있다. In the present invention, the vitamin B2 is necessary for energy production in the body, and acts as a photosensitizer, thereby having a photodynamic pathogenic reduction effect, that is, a bacterial and viral extermination and annihilation effect. In addition, the vitamin B2 is characterized by having the highest content among those available on the market within the allowable range of the Ministry of Food and Drug Safety. Specifically, the vitamin B2 may be included in an amount of 38 to 42 parts by weight, and more specifically, may be included in an amount of 39 to 41 parts by weight.
구체적으로, 상기 조성물은 레드비트농축분말 8 내지 12 중량부, 강황추출물 8 내지 12 중량부, 홍삼분말 0.005 내지 0.025 중량부, 비타민B2 38 내지 42 중량부를 포함하고, 보다 구체적으로 레드비트농축분말 9 내지 11 중량부, 강황추출물 9 내지 11 중량부, 홍삼분말 0.01 내지 0.02 중량부, 비타민B2 39 내지 41 중량부를 포함할 수 있으며, 상기 혼합조성을 통해 항산화 및 면역력 개선의 상승 효과를 얻을 수 있다. 이에, 본 발명의 조성물에서 레드비트농축분말, 강황추출물, 홍삼분말 및 비타민B2의 함량이 상기 범위를 벗어날 경우, 항산화 효과가 떨어지고, 대식세포의 활성이 떨어져 면연력 향상이 저감된다.Specifically, the composition contains 8 to 12 parts by weight of red beet concentrate powder, 8 to 12 parts by weight of turmeric extract, 0.005 to 0.025 parts by weight of red ginseng powder, and 38 to 42 parts by weight of vitamin B2, and more specifically, it may contain 9 to 11 parts by weight of red beet concentrate powder, 9 to 11 parts by weight of turmeric extract, 0.01 to 0.02 parts by weight of red ginseng powder, and 39 to 41 parts by weight of vitamin B2, and a synergistic effect of antioxidant and immunity improvement can be obtained through the mixed composition. Accordingly, when the contents of red beet concentrate powder, turmeric extract, red ginseng powder, and vitamin B2 in the composition of the present invention are out of the above range, the antioxidant effect is reduced, the activity of macrophages is reduced, and the improvement of immunity is reduced.
본 발명에서, 상기 비타민B1은 탄수화물과 에너지 대상에 필요하다. 상기 조성물은 비타민B1 또는 비타민B1의 염으로 포함될 수 있고, 예컨대 비타민B1의 염으로 비타민B1염산염이 포함될 수 있다. 또한, 상기 비타민B1 또는 이의 염은 0.15 내지 0.35 중량부로 포함될 수 있고, 구체적으로 0.2 내지 0.3 중량부로 포함될 수 있다.In the present invention, the vitamin B1 is necessary for carbohydrates and energy targets. The composition may be included as vitamin B1 or a salt of vitamin B1, and for example, vitamin B1 hydrochloride may be included as a salt of vitamin B1. In addition, the vitamin B1 or a salt thereof may be included in an amount of 0.15 to 0.35 parts by weight, and specifically, may be included in an amount of 0.2 to 0.3 parts by weight.
본 발명에서, 상기 니코틴산아미드는 비타민B3으로도 일려져 있으며, 비타민B2와 함께 체내 에너지 생성에 필요하다. 또한, 상기 니코틴산아미드는 1.5 내지 3.5 중량부로 포함될 수 있고, 구체적으로 2 내지 3 중량부로 포함될 수 있다.In the present invention, the nicotinic acid amide is also known as vitamin B3 and is necessary for energy production in the body together with vitamin B2. In addition, the nicotinic acid amide may be included in an amount of 1.5 to 3.5 parts by weight, and specifically, may be included in an amount of 2 to 3 parts by weight.
본 발명에서, 상기 판토텐산칼슘은 비타민B5로 알려져 있으며, 지방, 탄수화물, 단백질 대사와 에너지 생성에 필요하고, 염증을 조절하고, 면역력을 높이는 호르몬의 분비를 돕는다. 또한, 상기 판토텐산칼슘은 0.6 내지 1 중량부로 포함될 수 있고, 0.8 내지 1 중량부로 포함될 수 있다.In the present invention, the calcium pantothenate is known as vitamin B5, and is necessary for fat, carbohydrate, and protein metabolism and energy production, and helps secretion of hormones that control inflammation and enhance immunity. In addition, the calcium pantothenate may be included in an amount of 0.6 to 1 part by weight, and may be included in an amount of 0.8 to 1 part by weight.
본 발명에서, 상기 비타민B6은 단백질 및 아미노산 이용에 필요하고, 혈액의 호모시스테인 수준을 정상으로 유지하는 데 필요하다. 상기 조성물은 비타민B6 또는 비타민B6의 염으로 포함될 수 있고, 예컨대 비타민B6의 염으로 비타민B6염산염이 포함될 수 있다. 또한, 상기 비타민B6 또는 이의 염은 0.2 내지 0.35 중량부로 포함될 수 있고, 구체적으로 0.2 내지 0.3 중량부로 포함될 수 있다.In the present invention, the vitamin B6 is necessary for the utilization of proteins and amino acids, and is necessary for maintaining the homocysteine level of blood at a normal level. The composition may include vitamin B6 or a salt of vitamin B6, and for example, vitamin B6 hydrochloride may be included as a salt of vitamin B6. In addition, the vitamin B6 or a salt thereof may be included in an amount of 0.2 to 0.35 parts by weight, and specifically, may be included in an amount of 0.2 to 0.3 parts by weight.
본 발명에서, 상기 비오틴은 지방, 탄수화물, 단백질 대사와 에너지 생성에 필요하다. 또한, 상기 비오틴은 0.003 내지 0.006 중량부로 포함될 수 있고, 구체적으로 0.004 내지 0.005 중량부로 포함될 수 있다.In the present invention, the biotin is necessary for fat, carbohydrate, protein metabolism and energy production. In addition, the biotin may be included in an amount of 0.003 to 0.006 parts by weight, and specifically, may be included in an amount of 0.004 to 0.005 parts by weight.
본 발명에서, 상기 엽산은 세포와 혈액생성 및 혈액의 호모시스테인 수준을 정상으로 유지하는 데 필요하다. 또한, 상기 엽산은 0.03 내지 0.1 중량부로 포함될 수 있고, 구체적으로 0.05 내지 0.1 중량부로 포함될 수 있다.In the present invention, the folic acid is necessary for cell and blood production and maintaining the homocysteine level of blood at normal levels. In addition, the folic acid may be included in an amount of 0.03 to 0.1 parts by weight, and specifically, may be included in an amount of 0.05 to 0.1 parts by weight.
본 발명에서, 상기 아셀렌산나트륨혼합제제는 아셀렌산나트륨 및 제이인산칼슘으로 구성된 것으로, 시판상품을 구입하여 사용할 수 있다. 상기 아셀렌산나트륨은 무기셀레늄으로 항산화, 면역기능, 항암 효과가 있다. 또한, 상기 아셀렌산나트륨혼합제제는 0.6 내지 1 중량부로 포함될 수 있고, 구체적으로 0.7 내지 0.9 중량부로 포함될 수 있다.In the present invention, the sodium selenite mixture is composed of sodium selenite and dibasic calcium phosphate, and a commercial product can be purchased and used. The sodium selenite is an inorganic selenium, and has antioxidant, immune function, and anticancer effects. In addition, the sodium selenite mixture can be included in an amount of 0.6 to 1 part by weight, and specifically, can be included in an amount of 0.7 to 0.9 parts by weight.
본 발명에서, 상기 비타민C는 결합조직 형성과 기능유지, 철의 흡수에 필요하며, 항산화 작용을 한다. 또한, 상기 비타민C는 13 내지 17 중량부로 포함될 수 있고, 구체적으로 14 내지 16 중량부로 포함될 수 있다.In the present invention, the vitamin C is necessary for the formation and maintenance of connective tissue function, absorption of iron, and has an antioxidant effect. In addition, the vitamin C may be included in an amount of 13 to 17 parts by weight, and specifically, may be included in an amount of 14 to 16 parts by weight.
본 발명에서, 상기 비타민D3혼합제제는 비타민D3, 중쇄중성지방, dl-α-토코페롤로 구성된 것으로, 시판상품을 구입하여 사용할 수 있다. 상기 비타민D3는 칼슘 흡수를 돕고, 면역 기능을 조절한다. 또한, 상기 비타민D3혼합제제는 0.3 내지 1 중량부로 포함될 수 있고, 0.5 내지 0.8 중량부로 포함될 수 있다.In the present invention, the vitamin D3 mixed preparation is composed of vitamin D3, medium-chain triglycerides, and dl-α-tocopherol, and a commercial product can be purchased and used. The vitamin D3 helps calcium absorption and regulates immune function. In addition, the vitamin D3 mixed preparation can be included in an amount of 0.3 to 1 part by weight, and can be included in an amount of 0.5 to 0.8 parts by weight.
본 발명에서, 상기 건조효모는 크롬을 포함하며, 시판상품을 구입하여 사용할 수 있다. 상기 크롬은 체내 탄수화물, 지방, 단백질 대사에 관여한다. 또한, 상기 건조효모는 1.5 내지 3.5 중량부로 포함될 수 있고, 구체적으로 2 내지 3 중량부로 포함될 수 있다.In the present invention, the dry yeast contains chromium, and a commercially available product can be purchased and used. The chromium is involved in carbohydrate, fat, and protein metabolism in the body. In addition, the dry yeast can be included in an amount of 1.5 to 3.5 parts by weight, and specifically, can be included in an amount of 2 to 3 parts by weight.
본 발명에서, 상기 산화아연은 정상적인 면역 기능 및 세포분열에 필요하다. 또한, 상기 산화아연은 1 내지 2.5 중량부로 포함될 수 있고, 구체적으로 1 내지 2 중량부로 포함될 수 있다.In the present invention, the zinc oxide is necessary for normal immune function and cell division. In addition, the zinc oxide may be included in an amount of 1 to 2.5 parts by weight, and specifically, may be included in an amount of 1 to 2 parts by weight.
본 발명에서, 상기 황산망간은 신진대사에 관여하고, 두뇌나 간 등의 여러 장기가 정상적인 기능을 하는 데 필요하다. 상기 조성물은 황산망간 대신 글루콘산 망간, 염화망간 또는 구연산망간을 포함할 수 있다. 또한, 상기 황산망간은 1 내지 2.5 중량부로 포함될 수 있고, 구체적으로 1 내지 2 중량부로 포함될 수 있다.In the present invention, the manganese sulfate is involved in metabolism and is necessary for normal functioning of various organs such as the brain and liver. The composition may contain manganese gluconate, manganese chloride or manganese citrate instead of manganese sulfate. In addition, the manganese sulfate may be included in an amount of 1 to 2.5 parts by weight, and specifically, may be included in an amount of 1 to 2 parts by weight.
본 발명에서, 상기 히알루론산혼합제제는 덱스트린 및 히알루론산으로 구성된 것으로, 시판상품을 구입하여 사용할 수 있다. 상기 히알루론산은 피부보습에 도움을 준다. 또한, 상기 히알루론산혼합제제는 0.0005 내지 0.002 중량부로 포함될 수 있고, 구체적으로 0.0007 내지 0.0015 중량부로 포함될 수 있다.In the present invention, the hyaluronic acid mixture is composed of dextrin and hyaluronic acid, and a commercially available product can be purchased and used. The hyaluronic acid helps moisturize the skin. In addition, the hyaluronic acid mixture can be included in an amount of 0.0005 to 0.002 parts by weight, and specifically, can be included in an amount of 0.0007 to 0.0015 parts by weight.
본 발명에서, 상기 L-글루타치온 효모추출물은 글라이신, 시스테인 및 글루탐산이 결합한 물질로, 항산화 작용이 있고, 간의 대사 과정을 돕는다. 또한, 상기 L-글루타치온 효모추출물은 0.0005 내지 0.002 중량부로 포함될 수 있고, 구체적으로 0.0007 내지 0.0015 중량부로 포함될 수 있다.In the present invention, the L-glutathione yeast extract is a substance in which glycine, cysteine, and glutamic acid are combined, has an antioxidant effect, and helps the metabolic process of the liver. In addition, the L-glutathione yeast extract may be included in an amount of 0.0005 to 0.002 parts by weight, and specifically, may be included in an amount of 0.0007 to 0.0015 parts by weight.
본 발명에서, 상기 스테아린산마그네슘은 0.5 내지 1.5 중량부로 포함될 수 있고, 구체적으로 0.5 내지 1 중량부로 포함될 수 있다.In the present invention, the magnesium stearate may be included in an amount of 0.5 to 1.5 parts by weight, and specifically, may be included in an amount of 0.5 to 1 part by weight.
본 발명에서, 상기 이산화규소는 면역력 증강 및 만성피로 개선 효과가 있다. 또한, 상기 이산화규소는 0.5 내지 1.5 중량부로 포함될 수 있고, 구체적으로 0.5 내지 1 중량부로 포함될 수 있다.In the present invention, the silicon dioxide has the effect of enhancing immunity and improving chronic fatigue. In addition, the silicon dioxide may be included in an amount of 0.5 to 1.5 parts by weight, and specifically, may be included in an amount of 0.5 to 1 part by weight.
본 발명에서, 상기 하이드록시프로필 셀룰로오스(hydroxypropyl cellulose)는 0.5 내지 1.5 중량부로 포함될 수 있고, 구체적으로 0.5 내지 1 중량부로 포함될 수 있다.In the present invention, the hydroxypropyl cellulose may be included in an amount of 0.5 to 1.5 parts by weight, and specifically, may be included in an amount of 0.5 to 1 part by weight.
본 발명에서, 상기 정제 포도당은 뇌의 활동량을 증진시켜 집중력을 좋게 하고, 피로회복과 기력을 좋게 하여 신진대사를 활발하게 하며, 성장기 유아, 소아 및 청소년의 근성장을 돕는다. 또한, 상기 정제 포도당은 9 내지 12 중량부로 포함될 수 있다.In the present invention, the purified glucose increases brain activity, improves concentration, improves fatigue recovery and stamina, activates metabolism, and helps muscle growth in growing infants, children, and adolescents. In addition, the purified glucose may be included in an amount of 9 to 12 parts by weight.
구체적으로, 상기 조성물은 비타민B1 또는 이의 염 0.15 내지 0.35 중량부, 니코틴산아미드 1.5 내지 3.5 중량부, 판토텐산칼슘 0.6 내지 1 중량부, 비타민B6 또는 이의 염 0.2 내지 0.35 중량부, 비오틴 0.003 내지 0.006 중량부, 엽산 0.03 내지 0.1 중량부, 아셀렌산나트륨혼합제제 0.6 내지 1 중량부, 비타민C 13 내지 17 중량부, 비타민D3혼합제제 0.3 내지 1 중량부, 건조효모 1.5 내지 3.5 중량부, 산화아연 1 내지 2.5 중량부, 황산망간 1 내지 2.5 중량부, 히알루론산혼합제제 0.0005 내지 0.002 중량부, L-글루타치온 효모추출물 0.0005 내지 0.002 중량부, 스테아린산마그네슘 0.5 내지 1.5 중량부, 이산화규소 0.5 내지 1.5 중량부, 하이드록시프로필 셀룰로오스 0.5 내지 1.5 중량부 및 정제포도당 9 내지 12 중량부를 포함할 수 있다.Specifically, the composition comprises 0.15 to 0.35 parts by weight of vitamin B1 or a salt thereof, 1.5 to 3.5 parts by weight of nicotinamide, 0.6 to 1 part by weight of calcium pantothenate, 0.2 to 0.35 parts by weight of vitamin B6 or a salt thereof, 0.003 to 0.006 parts by weight of biotin, 0.03 to 0.1 parts by weight of folic acid, 0.6 to 1 part by weight of a sodium selenite mixture, 13 to 17 parts by weight of vitamin C, 0.3 to 1 part by weight of a vitamin D3 mixture, 1.5 to 3.5 parts by weight of dried yeast, 1 to 2.5 parts by weight of zinc oxide, 1 to 2.5 parts by weight of manganese sulfate, 0.0005 to 0.002 parts by weight of a hyaluronic acid mixture, and L-glutathione yeast extract. It may include 0.0005 to 0.002 parts by weight of sodium bicarbonate, 0.5 to 1.5 parts by weight of magnesium stearate, 0.5 to 1.5 parts by weight of silicon dioxide, 0.5 to 1.5 parts by weight of hydroxypropyl cellulose, and 9 to 12 parts by weight of refined glucose.
즉, 상기와 같이 구성된 본 발명의 건강기능식품은 체내 탄수화물, 지방, 단백질 대사와 에너지 생성을 도울 뿐만 아니라, 보다 향상된 항산화 및 면역력 증진 효과를 갖는다.That is, the health functional food of the present invention, composed as described above, not only helps the body's carbohydrate, fat, and protein metabolism and energy production, but also has improved antioxidant and immunity-boosting effects.
또한, 본 발명의 건강기능식품에 함유되는 성분은 모두 식품재료 및 식품으로 사용되는 것으로, 세포 독성이 없고 복용 또는 섭취시 인체에 대한 안전성이 우수하다.In addition, all ingredients contained in the health functional food of the present invention are used as food materials and foods, are non-cytotoxic, and are excellently safe for the human body when taken or consumed.
본 발명의 건강보조식품은 통상의 제조방법에 따라 분말, 캡슐, 산제, 정제, 과립, 엑기스 또는 음료 등의 형태로 제형화할 수 있다. 이때, 제형화를 위하여 공지된 식품첨가성분이 더 첨가될 수 있음은 당연하다.The health supplement of the present invention can be formulated in the form of powder, capsule, powder, tablet, granule, extract or beverage, etc., according to a conventional manufacturing method. At this time, it goes without saying that a known food additive may be further added for formulation.
본 발명의 건강보조식품은 연령, 체중에 따라 적량을 선택하여 섭취할 수 있으며, 1일 500mg 내지 4000mg의 섭취로 충분한 효과를 얻을 수 있다. 상기 섭취량은 1회 또는 2회 이상으로 나누어 복용할 수 있으며, 바로 씹어서 먹거나, 물이나 우유와 같이 섭취하는 것도 가능하다.The health supplement of the present invention can be taken in an appropriate amount according to age and weight, and sufficient effects can be obtained by taking 500 mg to 4000 mg per day. The above-mentioned amount can be taken once or in two or more divided doses, and can be eaten by chewing it directly, or taken with water or milk.
이하, 본 발명을 실시예에 의해 상세히 설명한다.Hereinafter, the present invention will be described in detail by examples.
단, 하기 실시예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기 실시예에 한정되는 것은 아니다.However, the following examples are only intended to illustrate the present invention, and the content of the present invention is not limited to the following examples.
<실시예 1 및 비교예 1 내지 4> 면역증강용 건강기능식품 조성물의 제조<Example 1 and Comparative Examples 1 to 4> Preparation of health functional food composition for enhancing immunity
하기 표 1의 조성으로 각 성분을 혼합하고, 이를 타정기로 타정하여 정제(1정당 700 mg)로 제조하였다.Each component was mixed according to the composition in Table 1 below, and pressed into tablets (700 mg per tablet) using a tablet press.
<실험예 1> 세포 독성 평가<Experimental Example 1> Cytotoxicity Evaluation
상기 실시예 1, 비교예 1 내지 4의 세포독성을 평가하였다.The cytotoxicity of the above Example 1 and Comparative Examples 1 to 4 was evaluated.
구체적으로, RAW 264.7 세포를 96-웰 플레이트에 2×104 cell/웰의 세포수로 100 ul씩 분주하고 37℃, 5% CO2 인큐베이터에서 24시간 배양한 후 시료를 100 ug/mL의 농도로 처리하여 24시간 동안 배양하였다. 또한, 정상 대조군은 상기 시료를 0 ug/mL로 처리하고, 양성 대조군으로 지방질 다당류(LPS)를 1 ug/mL로 처리하였다. 이후 0.2 ㎎/㎖ 농도의 MTT solution을 각 웰에 100 ul씩 넣고 2시간 동안 배양한 후 상층액을 제거하고 DMSO를 100 ul씩 분주하여 formazan을 잘 녹인 후 570 nm에서 흡광도를 측정하였다. Specifically, RAW 264.7 cells were seeded at 2 × 10 4 cells/well in 96-well plates (100 μl) and cultured for 24 hours in a 37°C, 5% CO 2 incubator. The cells were treated with 100 μg/mL of the sample and cultured for 24 hours. In addition, the normal control group was treated with 0 μg/mL of the sample, and the positive control group was treated with 1 μg/mL of lipopolysaccharide (LPS). After that, 100 μl of 0.2 mg/mL MTT solution was added to each well and cultured for 2 hours. The supernatant was removed, and 100 μl of DMSO was added to thoroughly dissolve the formazan, and the absorbance was measured at 570 nm.
그 결과, 도 1에 나타낸 바와 같이, 실시예 1, 비교예 1 내지 4 모두 세포 독성이 나타나지 않음을 확인하였다.As a result, as shown in Fig. 1, it was confirmed that none of Example 1 and Comparative Examples 1 to 4 exhibited cytotoxicity.
<실험예 2> NO 생성 측정<Experimental Example 2> Measurement of NO production
대식세포(macrophage)는 선천면역계에서 중요한 역할을 수행하는 면역세포로, 이들이 활성화되면 탐식작용, 항원-항체복합체 제거 및 선천면역계 조절작용 등으로 생체 면역증진에 중요하게 관여할 뿐만 아니라, 활성 산소종 및 산화질소(nitric oxide, NO) 등의 생산을 증가시켜 외부에서 침입한 병원체 및 항원을 제거하고, 대식세포는 항원제시세포로 작용하여 항원 특이적인 후천면역계를 유도하게 된다. 이에, 상기 실시예 1, 비교예 1 내지 4가 면역활성이 미치는 영향을 알아보기 위해, 대식세포를 이용하여 세포배양액 중에 존재하는 NO2-의 생성 농도를 측정하였다. Macrophages are immune cells that play an important role in the innate immune system. When activated, they are not only significantly involved in promoting the body's immunity through phagocytosis, removal of antigen-antibody complexes, and regulation of the innate immune system, but also increase the production of reactive oxygen species and nitric oxide (NO) to remove pathogens and antigens that have invaded from the outside, and macrophages act as antigen-presenting cells to induce an antigen-specific acquired immune system. Accordingly, in order to determine the effect of Example 1 and Comparative Examples 1 to 4 on immune activity, the concentration of NO 2- produced in a cell culture solution using macrophages was measured.
구체적으로, RAW 264.7 세포를 6-웰 플레이트에 5×105 세포수/웰의 농도로 분주하여 24시간 배양한 후에 각 제조된 시료 100 ug/mL를 각각 처리하였다. 정상 대조군은 상기 시료를 0 ug/mL로 처리하고, 양성 대조군으로 지방질 다당류(LPS)를 1 ug/mL로 처리하여 24시간 동안 배양하였다. 세포 배양액의 상층액과 동량의 griess reagent를 혼합하여 상온에서 15분 반응시킨 후 540 nm에서 흡광도를 측정하였으며, 아질산소듐(sodium nitrite)을 이용하여 작성한 표준곡선으로부터 산화질소 농도를 구하여 환산하였다.Specifically, RAW 264.7 cells were seeded in a 6-well plate at a density of 5 × 10 5 cells/well and cultured for 24 hours, after which each prepared sample was treated at 100 ug/mL. The normal control group was treated with 0 ug/mL of the above sample, and the positive control group was treated with 1 ug/mL of lipopolysaccharide (LPS) and cultured for 24 hours. The supernatant of the cell culture medium and an equal amount of Griess reagent were mixed and reacted at room temperature for 15 minutes, and the absorbance was measured at 540 nm. The nitric oxide concentration was calculated from a standard curve created using sodium nitrite and converted.
그 결과, 도 2에 나타낸 바와 같이, 실시예 1에서 대조군 대비 NO 생산이 촉진되는 것을 확인하였다. 또한, 비교예 1 내지 5에 비해서도 실시예 1의 혼합조성에서 NO 생산의 상승효과가 나타남을 확인하였다.As a result, as shown in Fig. 2, it was confirmed that NO production was promoted in Example 1 compared to the control group. In addition, it was confirmed that a synergistic effect of NO production was observed in the mixed composition of Example 1 compared to Comparative Examples 1 to 5.
<실험예 3> 사이토카인 생성 측정<Experimental Example 3> Measurement of cytokine production
활성화된 대식세포는 IL-1, IL-6 및 TNF-α와 같은 다양한 사이토카인을 분비하여 후천면역계를 활성화시킨다. 이에, 상기 실시예 1, 비교예 1 내지 4가 면역활성이 미치는 영향을 알아보기 위해, 대식세포를 이용하여 세포배양액 중에 분비된 사이토카인 TNF-α 및 IL-6를 측정하였다. Activated macrophages secrete various cytokines such as IL-1, IL-6, and TNF-α, thereby activating the adaptive immune system. Accordingly, in order to determine the effects of Example 1 and Comparative Examples 1 to 4 on immune activity, cytokines TNF-α and IL-6 secreted in cell culture media using macrophages were measured.
구체적으로, 상기 <실험예 2>에 기재된 방법과 동일한 방법으로 RAW 264.7 세포에 시료를 처리한 후 세포 상층액을 획득한 후, TNF-α 및 IL-6 ELISA kit(BD Bioscience, USA)를 이용하여 제조사의 절차에 따라 TNF-α 및 IL-6 각각의 농도를 측정하였다.Specifically, RAW 264.7 cells were treated with a sample using the same method as described in <Experimental Example 2> above, and then cell supernatants were obtained. Then, the concentrations of TNF-α and IL-6 were measured using TNF-α and IL-6 ELISA kits (BD Bioscience, USA) according to the manufacturer's procedure.
그 결과, 도 3 및 도 4에 나타낸 바와 같이, 실시예 1에서 대조군 대비 TNF-α 및 IL-6 생산이 증가하는 것을 확인하였다. 또한, 비교예 1 내지 5에 비해서도 실시예 1의 혼합조성에서 TNF-α 및 IL-6 생산의 상승효과가 나타남을 확인하였다.As a result, as shown in FIGS. 3 and 4, it was confirmed that TNF-α and IL-6 production increased compared to the control group in Example 1. In addition, it was confirmed that a synergistic effect on TNF-α and IL-6 production was observed in the mixed composition of Example 1 compared to Comparative Examples 1 to 5.
<실험예 4> 항산화 활성 평가<Experimental Example 4> Antioxidant activity evaluation
상기 실시예 1, 비교예 1 내지 5의 항산화 활성을 확인하였다.The antioxidant activity of the above Example 1 and Comparative Examples 1 to 5 was confirmed.
구체적으로, 상기 실시예 1, 비교예 1 내지 5의 항산화 활성을 평가하기 위하여 DPPH 라디칼 소거능 실험(DPPH radical scavenging activity)을 진행하였다. DPPH 라디컬 소거활성은 Sharma OP, Bhat TK (2009)의 방법에 의하여 측정하였다. 시료를 0.2% DMSO에 녹인 후 시료 용액 0.2 mL를 0.2 mM의 DPPH 용액 0.8 mL에 첨가하여 혼합한 다음 실온에서 30분간 반응시킨 후 517 nm에서 흡광도를 측정하였다. 항산화력은 [1-(시료첨가구의 흡광도/무첨가구의 흡광도)]×10 의 계산식에 의해 전자공여능(%)을 구하였다.Specifically, in order to evaluate the antioxidant activity of Example 1 and Comparative Examples 1 to 5, a DPPH radical scavenging activity experiment was conducted. The DPPH radical scavenging activity was measured by the method of Sharma OP, Bhat TK (2009). The sample was dissolved in 0.2% DMSO, and 0.2 mL of the sample solution was added to 0.8 mL of a 0.2 mM DPPH solution, mixed, and reacted at room temperature for 30 minutes, after which the absorbance was measured at 517 nm. The antioxidant power was calculated as the electron donating ability (%) by the calculation formula [1-(absorbance of the sample addition group/absorbance of the non-added group)] × 10.
(100 mg/100 mL)DPPH Radical scavenging activity (%)
(100 mg/100 mL)
그 결과, 표 2에 나타낸 바와 같이, 비교예 1 내지 5 대비 실시예 1에서 항산화 효과가 현저히 우수함을 확인하였다. As a result, as shown in Table 2, it was confirmed that the antioxidant effect was significantly superior in Example 1 compared to Comparative Examples 1 to 5.
이상으로 본 발명의 특정한 부분을 상세히 기술하였는바, 당 업계의 통상의 지식을 가진 자에게 있어서 이러한 구체적인 기술은 단지 바람직한 구현예일 뿐이며, 이에 본 발명의 범위가 제한되는 것이 아닌 점은 명백하다. 따라서, 본 발명의 실질적인 범위는 첨부된 청구항과 그의 등가물에 의하여 정의된다고 할 것이다.While the specific parts of the present invention have been described in detail above, it is obvious to those skilled in the art that such specific descriptions are merely preferred embodiments and that the scope of the present invention is not limited thereto. Accordingly, the actual scope of the present invention will be defined by the appended claims and their equivalents.
Claims (6)
Red beet concentrate powder 8 to 12 parts by weight, turmeric extract 8 to 12 parts by weight, red ginseng powder 0.005 to 0.025 parts by weight, vitamin B2 38 to 42 parts by weight, vitamin B1 or a salt thereof 0.15 to 0.35 parts by weight, nicotinamide 1.5 to 3.5 parts by weight, calcium pantothenate 0.6 to 1 part by weight, vitamin B6 or a salt thereof 0.2 to 0.35 parts by weight, biotin 0.003 to 0.006 parts by weight, folic acid 0.03 to 0.1 part by weight, sodium selenite mixed preparation 0.6 to 1 part by weight, vitamin C 13 to 17 parts by weight, vitamin D3 mixed preparation 0.3 to 1 part by weight, dried yeast 1.5 to 3.5 parts by weight, zinc oxide 1 to An antioxidant and immune-enhancing health functional food composition comprising 2.5 parts by weight of manganese sulfate, 1 to 2.5 parts by weight of a hyaluronic acid mixture, 0.0005 to 0.002 parts by weight of L-glutathione yeast extract, 0.5 to 1.5 parts by weight of magnesium stearate, 0.5 to 1.5 parts by weight of silicon dioxide, 0.5 to 1.5 parts by weight of hydroxypropyl cellulose, and 9 to 12 parts by weight of refined glucose.
A health functional food composition for antioxidant and immune enhancement, wherein the salt of vitamin B1 in claim 1 is vitamin B1 hydrochloride.
A health functional food composition for antioxidant and immune enhancement, wherein the salt of vitamin B6 in claim 1 is vitamin B6 hydrochloride.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020240049858A KR102717772B1 (en) | 2024-04-15 | 2024-04-15 | Health functional food composition for antioxidant activity and immune-enhancing |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020240049858A KR102717772B1 (en) | 2024-04-15 | 2024-04-15 | Health functional food composition for antioxidant activity and immune-enhancing |
Publications (1)
Publication Number | Publication Date |
---|---|
KR102717772B1 true KR102717772B1 (en) | 2024-10-15 |
Family
ID=93115015
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020240049858A KR102717772B1 (en) | 2024-04-15 | 2024-04-15 | Health functional food composition for antioxidant activity and immune-enhancing |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102717772B1 (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102270923B1 (en) | 2020-04-02 | 2021-06-30 | (주) 바이노텍 | Composition for improving immunity including fermented blueberry and black rice extracts |
-
2024
- 2024-04-15 KR KR1020240049858A patent/KR102717772B1/en active IP Right Grant
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102270923B1 (en) | 2020-04-02 | 2021-06-30 | (주) 바이노텍 | Composition for improving immunity including fermented blueberry and black rice extracts |
Non-Patent Citations (5)
Title |
---|
Bokov A, Chaudhuri A, Richardson A. 2004. The role of oxidative damage and stress in aging. Mechanisms of Ageing and Development 125:811-826. |
Cadenas E, Davies KJ. 2000. Mitochodrial free radical generation, oxidative stress, and aging. Free Radical Biology & Medicine 29:222-230 |
네이버 블로그에 게재된 ‘면역비타힘 리뷰’(2023.08.23.)* * |
네이버 블로그에 게재된 ‘비타글로우 피부건강위한 고함량 비타민C 함유+’(2022.06.22.)* * |
네이버 블로그에 게재된 ‘장대원 코엔자임 C10 항산화플러스’(2024.02.01.)* * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Yadav et al. | Bioactive components of mushrooms: Processing effects and health benefits | |
JPWO2006093267A1 (en) | Fermentation composition having immunomodulatory action | |
WO2008014674A1 (en) | A nutritional and health-care edible potassium salt with wide purpose | |
CN113925923B (en) | Anti-acne and whitening compound probiotic composition and preparation method thereof | |
CN110432482A (en) | A kind of infant allergic dermatitis tailored version clinical nutrition formula and preparation method thereof | |
KR102178926B1 (en) | A composition for reinforcing immune function and anti-fatigue comprising fermented placenta and its use | |
KR101896024B1 (en) | Functional food compositions comprising extracts of Garcinia Cambogia as active ingredients and method for preparing the same | |
KR20140067826A (en) | Composition comprising sargassum fulvellum extract for preventing or treating inflammatory diseases | |
CN105685628A (en) | Compound calcium chewable tablets and preparation method thereof | |
KR102717772B1 (en) | Health functional food composition for antioxidant activity and immune-enhancing | |
CN102018158A (en) | Aloe jam | |
ES2731588T3 (en) | Prepared yeast flour and procedure for use | |
KR101626642B1 (en) | Composition comprising fermented extract of trifoliate orange for improving diabetes | |
KR20170077640A (en) | Composition for Relaxing Stress and Immunopotentiating Using Red Ginseng Power, etc. | |
CN110584120A (en) | Bone health composition | |
RU2492867C1 (en) | Biologically active additive | |
KR102368892B1 (en) | A composition for anti-inflammatory comprising extracts of single leaf cremastra and sigesbeckia glabrescens makino | |
KR102534513B1 (en) | Composition showing antioxidant and immunity improving activity containing callophyllis rhynchocarpa extract, and health functional food containing the same | |
KR20200043555A (en) | Supplement food composition for diet | |
CN114680339A (en) | Nutritional supplement for improving muscle attenuation and delaying senescence and application thereof | |
KR101135961B1 (en) | An antihyperlipidemia composition comprising purple bamboo salt | |
CN113841884A (en) | Formula of instant meal replacement powder for improving nutrient metabolism and preparation method thereof | |
JP3171526B2 (en) | Active oxygen scavenging food | |
KR20220057839A (en) | Manufacturing method of food composition for immune-enhancing activity comprising juice of Cirsium setidens, and food composition for immune-enhancing activity using thereby | |
CN110679935A (en) | Burdock and ginseng essence cream and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |